Correlation Engine 2.0
Clear Search sequence regions


  • africa (2)
  • alleles (8)
  • bupropion (1)
  • CYP2A6 (9)
  • cyp2a6 protein human (1)
  • CYP2B6 (11)
  • gene frequency (1)
  • genes (2)
  • genomes (2)
  • humans (1)
  • P 450 (4)
  • phenotypes (1)
  • protein human (2)
  • sahara (1)
  • smoking (1)
  • Sizes of these terms reflect their relevance to your search.

    Genetic variation in CYP2B6 and CYP2A6 is known to impact interindividual response to antiretrovirals, nicotine, and bupropion, among other drugs. However, the full catalogue of clinically relevant pharmacogenetic variants in these genes is yet to be established, especially across African populations. This study therefore aimed to characterize the star allele (haplotype) distribution in CYP2B6 and CYP2A6 across diverse and understudied sub-Saharan African (SSA) populations. We called star alleles from 961 high-depth full genomes using StellarPGx, Aldy, and PyPGx. In addition, we performed CYP2B6 and CYP2A6 star allele frequency comparisons between SSA and other global biogeographical groups represented in the new 1000 Genomes Project high-coverage dataset (n = 2,000). This study presents frequency information for star alleles in CYP2B6 (e.g., *6 and *18; frequency of 21-47% and 2-19%, respectively) and CYP2A6 (e.g., *4, *9, and *17; frequency of 0-6%, 3-10%, and 6-20%, respectively), and predicted phenotypes (for CYP2B6), across various African populations. In addition, 50 potentially novel African-ancestry star alleles were computationally predicted by StellarPGx in CYP2B6 and CYP2A6 combined. For each of these genes, over 4% of the study participants had predicted novel star alleles. Three novel star alleles in CYP2A6 (*54, *55, and *56) and CYP2B6 apiece, and several suballeles were further validated via targeted Single-Molecule Real-Time resequencing. Our findings are important for informing the design of comprehensive pharmacogenetic testing platforms, and are highly relevant for personalized medicine strategies, especially relating to antiretroviral medication and smoking cessation treatment in Africa and the African diaspora. More broadly, this study highlights the importance of sampling diverse African ethnolinguistic groups for accurate characterization of the pharmacogene variation landscape across the continent. © 2023 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

    Citation

    David Twesigomwe, Britt I Drögemöller, Galen E B Wright, Clement Adebamowo, Godfred Agongo, Palwendé R Boua, Mogomotsi Matshaba, Maria Paximadis, Michèle Ramsay, Gustave Simo, Martin C Simuunza, Caroline T Tiemessen, Zané Lombard, Scott Hazelhurst. Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub-Saharan African Populations. Clinical pharmacology and therapeutics. 2024 Mar;115(3):576-594

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 38049200

    View Full Text